8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Sep 11, 2008)

Filed September 11, 2008For Securities:BMYCELG-RIBMYMP

Summary

This 8-K filing by Bristol-Myers Squibb (BMY) on September 11, 2008, primarily reports on a letter sent by BMY to the Board of Directors of ImClone Systems Incorporated on the same date. The details of this communication are provided via an attached press release, which is incorporated by reference into the filing. While the specific contents of the letter are not fully disclosed within the 8-K itself, its existence suggests a significant development or ongoing discussion between Bristol-Myers Squibb and ImClone Systems. Investors should pay close attention to the attached press release (Exhibit 99.1) for further clarification on the nature of this communication and its potential implications for both companies. This event could relate to strategic partnerships, potential M&A activity, or other significant corporate actions that might impact BMY's future performance and its relationship with ImClone. Further analysis of the press release is crucial to understand the full context and potential impact on shareholders.

Key Highlights

  • 1Bristol-Myers Squibb (BMY) filed an 8-K on September 11, 2008.
  • 2The filing primarily concerns a letter sent by BMY to the Board of Directors of ImClone Systems Incorporated on September 11, 2008.
  • 3A press release containing the full text of the letter is attached as Exhibit 99.1 and incorporated by reference.
  • 4The specific details of the letter's content are not elaborated within the 8-K itself.
  • 5This event suggests a significant interaction or development between BMY and ImClone Systems.
  • 6Investors are directed to Exhibit 99.1 for more information regarding the communication.

Frequently Asked Questions

The main purpose of this 8-K filing is to report that Bristol-Myers Squibb (BMY) sent a letter to the Board of Directors of ImClone Systems Incorporated on September 11, 2008. The details of this communication are provided in an attached press release.

The 8-K filing itself does not disclose the specific content of the letter sent to ImClone Systems. However, it states that the full text of the letter is included in the press release attached as Exhibit 99.1.

This event is significant because it indicates a material communication between Bristol-Myers Squibb and ImClone Systems. Such communications can relate to strategic decisions, potential collaborations, mergers, acquisitions, or other corporate actions that could impact BMY's business and shareholder value. Investors need to review the accompanying press release for full context.

More details about the communication, including the full text of the letter, can be found in the press release dated September 11, 2008, which is attached as Exhibit 99.1 to this 8-K filing.